Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Conditions: Mycosis Fungoides; Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Myco sis Fungoides and Sezary Syndrome AJCC v8; Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA2 M ycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 Intervention: Biological: Pembrolizumab Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials